REVIEW article

Front. Immunol.

Sec. Inflammation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1569915

The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC

Provisionally accepted
qiulin  Wuqiulin Wu1yan  Yangyan Yang1Shixun  LinShixun Lin1David  GellerDavid Geller2*Yihe  YanYihe Yan1*
  • 1Second Affiliated Hospital of Guangxi Medical University, Nanning, China
  • 2University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

The final, formatted version of the article will be published soon.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a series of obesity-related metabolic liver diseases, ranging from relatively benign hepatic steatosis to metabolic-associated steatohepatitis (MASH). With the changes in lifestyle, its incidence and prevalence have risen to epidemic proportions globally. In recent years, an increasing amount of evidence has indicated that the hepatic microenvironment is involved in the pathophysiological processes of MASH-induced liver fibrosis and the formation of hepatocellular carcinoma (HCC). The hepatic microenvironment is composed of various parenchymal and non -parenchymal cells, which communicate with each other through various factors. In this review, we focus on the changes in hepatocytes, cholangiocytes, liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), Kupffer cells (KC), dendritic cells (DC), neutrophils, monocytes, T and B lymphocytes, natural killer cells (NK), natural killer T cells (NKT), mucosal-associated invariant T cells (MAIT), γδT cells, and gut microbiota during the progression of MASLD. Furthermore, we discuss promising therapeutic strategies targeting the microenvironment of MASLD-MASH-HCC.

Keywords: microenvironment, MASLD, MASH, HCC, Therapeutics

Received: 07 Feb 2025; Accepted: 08 Apr 2025.

Copyright: © 2025 Wu, Yang, Lin, Geller and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
David Geller, University of Pittsburgh Medical Center, Pittsburgh, 15213, Pennsylvania, United States
Yihe Yan, Second Affiliated Hospital of Guangxi Medical University, Nanning, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more